Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

NCT04645797 is registered in ClinicalTrials.gov with Apros Therapeutics, Inc as lead sponsor.

NCT NCT04645797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04645797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
Lead sponsor
Apros Therapeutics, Inc
Phase
Phase 1
Overall status
Terminated
Start date
January 19, 2021
Completion date
May 7, 2022
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal carcinoma